Author:
Yonesaka Kimio,Takegawa Naoki,Watanabe Satomi,Haratani Koji,Kawakami Hisato,Sakai Kazuko,Chiba Yasutaka,Maeda Naoyuki,Kagari Takashi,Hirotani Kenji,Nishio Kazuto,Nakagawa Kazuhiko
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference30 articles.
1. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signalling, tumour biology, and cancer therapy. Clin Cancer Res. 2010;16:1373–83.
2. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol. 1997;10:142–8.
3. Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005;93:1334–40.
4. Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA. 2005;102:3788–93.
5. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science. 2007;316:1039–43.
Cited by
72 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献